What the FDA labels say about taking them together
Cyclobenzaprine and verapamil
Cyclobenzaprine's FDA label of February 21, 2025 names verapamil in its warnings section; the verapamil labels PlainMeds reads (4) do not name cyclobenzaprine. The cyclobenzaprine label: “… (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.”
Check it at the source: the cyclobenzaprine FDA label on DailyMed (effective February 21, 2025, Jubilant Cadista Pharmaceuticals Inc.); the verapamil FDA label on DailyMed (effective April 6, 2026, Zydus Pharmaceuticals (USA) Inc.).
What does the cyclobenzaprine label say about verapamil?
Cyclobenzaprine label, warningsWARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.
Cyclobenzaprine Hydrochloride label (Teva Pharmaceuticals USA, Inc., May 31, 2024), drug interactionsPostmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions ( 5.1 )].
Tonmya label (Tonix Medicines, Inc., August 14, 2026), drug interactionsPostmarketing cases of serotonin syndrome have been reported with the concomitant use of oral cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions (5.2) ].
Source: FDA drug label (Cyclobenzaprine Hydrochloride, NDA021777), Teva Pharmaceuticals USA, Inc., effective May 31, 2024 (SPL set ca74d27a-f7c6-462d-a913-1cfa061bd8f3), via openFDA
Source: FDA drug label (Tonmya, NDA219428), Tonix Medicines, Inc., effective August 14, 2026 (SPL set 6fa59588-ce9b-48cf-8c5f-725a448f8571), via openFDA
Source: FDA drug label (Cyclobenzaprine Hydrochloride), Jubilant Cadista Pharmaceuticals Inc., effective February 21, 2025 (SPL set 592871f6-0eb2-4624-9e10-bd8bf767c002), via openFDA; the full label on DailyMed
What does the verapamil label say about cyclobenzaprine?
Verapamil's label (effective April 6, 2026) and its 3 other brand-application labels do not name cyclobenzaprine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Verapamil hydrochloride), Zydus Pharmaceuticals (USA) Inc., effective April 6, 2026 (SPL set e19ab8d8-dae5-489d-9805-7e7407bea06d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclobenzaprine | Verapamil | |
|---|---|---|
| Labeled for | Muscle spasms and spasticity, Nerve pain and fibromyalgia | High blood pressure, Atrial fibrillation, Angina |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0171 per tablet 10 mg tablet | $0.191 per tablet 180 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once